

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Topper James N</u> (Last) (First) (Middle) <u>C/O FRAZIER HEALTHCARE PARTNERS</u> <u>601 UNION STREET, SUITE 3200</u> (Street) <u>SEATTLE WA 98101</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/29/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>NewAmsterdam Pharma Co N.V. [NAMS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	3,801,000	I	Frazier Lifesciences Sponsor LLC ⁽¹⁾
Ordinary Shares	3,000,000	I	Frazier Life Sciences X, L.P. ⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Warrant (right to buy)	12/23/2022	11/23/2027	Ordinary Shares	167,000	11.5	I	Frazier Lifesciences Sponsor LLC ⁽¹⁾
Warrant (right to buy)	12/23/2022	11/23/2027	Ordinary Shares	333,333	11.5	I	Frazier Life Sciences X, L.P. ⁽²⁾

Explanation of Responses:

1. The securities are held directly by Frazier Lifesciences Sponsor LLC ("Sponsor"). The sole member of Sponsor is Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper is one of two managing members of FHMLS X, L.L.C. Dr. Topper disclaims beneficial ownership of the securities held by FLS Sponsor except for his pecuniary interest therein, if any.

2. The securities are held directly by FLS X. FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper is one of two managing members of FHMLS X, L.L.C.. Dr. Topper disclaims beneficial ownership of the securities held by FLS X except for his pecuniary interest therein, if any.

/s/ James N. Topper 12/29/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.